Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03075696
Title A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

hematologic cancer

Therapies

Obinutuzumab + RO7082859 + Tocilizumab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | CAN | BEL


No variant requirements are available.